Biodistribution studies are essential for understanding the biologic behavior of novel fluorochrome-based molecular imaging agents.
T HE ENDOTHELIN (ET) AXIS is known to play a major role in the modulation of vascular tone, [1] [2] [3] [4] [5] as well as in the progression of various human cancer types. [6] [7] [8] [9] [10] [11] [12] Three isoforms of ET exist (ET-1, ET-2, and ET-3), exerting their effects via two different G protein-coupled receptors (ET A R, ET B R). Whereas ET A Rs are primarily located on vascular smooth muscle cells and are responsible for vasoconstriction and cell proliferation, ET B Rs are located on smooth muscle cells and vascular endothelial cells, causing vasodilation by the release of nitric oxide and prostacyclin, and are responsible for the clearance of ET-1 from plasma in lung tissue. 13 In oncology, ET-1 in particular, acting primarily through the ET A R, is associated with the neoplastic growth of multiple tumor types. ET antagonism inhibits tumor cell proliferation, invasiveness, and new vessel formation. Hence, therapeutic inhibition of ET A R is a concept that is currently under investigation for tumor treatment, especially in breast and prostate cancers. 14 In this context, a method for the visualization of receptor density in affected tissue would be invaluable for clinical diagnosis and the evaluation of therapy. Choosing optical imaging as the detection modality can be an attractive alternative to scintigraphic imaging techniques since it is relatively inexpensive, free of ionizing radiation and isotope decay, and applicable for tomographic (eg, fluorescence-mediated tomography [FMT] ) and surface-weighted (eg, fluorescence reflectance imaging [FRI]) imaging. These techniques allow the detection of molecules in picomolar concentrations, which is comparable to conventional scintigraphic imaging techniques. [15] [16] [17] The developed photoprobe, termed ET A -Cy5.5 (2; Figure 1 ), is based on PD 156707, a potent ET receptor antagonist with high affinity and ET A selectivity. [18] [19] [20] [21] The tracer was synthesized by reaction of Cy5.5 Nhydroxysuccinimidyl-(NHS-) ester with amino-precursor 1 (see Figure 1 ). 22 In this study, we examined the biodistribution of the tracer in wild-type CD-1 mice to assess the applicability of the probe to image ET A R expression in vivo.
Materials and Methods

General
All chemicals, reagents, and solvents for the preparation of the compounds were analytical grade and purchased from commercial sources. PD 156707 (3-benzo [1, 3] dioxol-5-yl-5-hydroxy-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-5H-furan-2-one) was prepared as reported and used as the sodium carboxylate salt. 23 Compound analysis was done by mass spectrometry using a Quattro LCZ spectrometer (Waters-Micromass, Manchester, UK) with a nanospray capillary inlet.
Preparation of ET A -Cy5.5 (2)
The ligand-dye conjugate ET A -Cy5.5 (2) was prepared according to the described procedure. 22 Briefly, aminoprecursor 1 was dissolved in bicarbonate buffer (0.1 M, pH 8.6) at 1.0 mM concentration, Cy5.5 NHS-ester was dissolved in dimethylsulfoxide at 1.0 mM concentration, and equal amounts of both solutions were mixed and stirred for 60 minutes at room temperature in the dark. The reaction mixture was then transferred to semipreparative reversed-phase high-performance liquid chromatography (RP-HPLC), using a Knauer system (Knauer Wissenschaftliche Gerätebau GmbH, Berlin, Germany) with two K-1800 pumps, an S-2500 ultraviolet (UV) detector, and a RP-HPLC Nucleosil 100-5 C18 column (250 3 4.6 mm). The conditions used were as follows: eluent A (water, 0.1% trifluoroacetic acid [TFA]); eluent B (acetonitrile, 0.1% TFA); gradient from 90% A to 40% A over 40 minutes at a flow rate of 1.5 mL/min, detection at l 5 254 nm. The appropriate fractions (t R 5 31 minutes) were collected, lyophilized, redissolved in phosphate-buffered saline, and finally stored at 220uC. The average content of 2 was 0.8 6 0.3 mmol/mL (< 60% yield) as determined by fluorometer measurements with l abs 5 678 nm and l 678 5 250,000 M 21 cm 21 (Hitachi U3310 UV/VIS spectrophotometer and Hitachi F-4500 fluorescence spectrometer, Tokyo, Japan).
Animals
Three-to 5-week-old female CD-1 mice (25-30 g; Charles-River WIGA, Sulzfeld, Germany) were used for all in vivo experiments. Animal studies were approved by the institu-tional animal care committee. Mice were anesthetized by intraperitoneal injection of a combination of ketamine and xylazine (90/10 mg per kilogram of body weight), and ET A -Cy5.5 (2.0 nmol) was injected into the tail vein. For injection of the photoprobe, a small insulin syringe was used (BD Micro-Fine +, 0.33 (29G) 3 12.7 mm). For predosing experiments, 2.0 mmol of PD 156707 was injected 10 minutes prior to injection of ET A -Cy5.5. At given time points (10 and 30 minutes and 1, 3, 5, 24, and 48 hours) after injection, mice (n 5 6-8 for each time point) were sacrificed by overdosing anesthesia. To clear blood from organs and tissue, the animals were perfused with ice-cold saline solution via the left ventricle of the heart. 24 Organs were rapidly removed, weighed, and subjected to FRI. For selected time points (1 hour and 24 hours; n 5 6-8), displacement experiments were performed, where 2.0 mmol of PD 156707 was given 10 minutes prior to sacrifice.
Fluorescence Reflectance Imaging
Explanted organs were cleaned from surrounding tissue and placed on a petri dish. Optical reflectance imaging was performed using the In-Vivo FX Imaging System (Kodak Molecular Imaging Systems, New Haven, CT). Illumination was provided by a 150 W halogen lamp with selectable bandpass excitation and emission filters. For Cy5.5 excitation, l 5 630 6 10 nm and emission l 5 700 6 17.5 nm filters were employed. Light from the fluorescence screen is captured with the 4-million pixel cooled charge-coupled device camera equipped with a 103 zoom lens. Image acquisition times were 30 seconds at the emission wavelength band. Optical images were coregistered with background (phase contrast) images, and regions of interest were selected and analyzed with the Kodak Molecular Imaging 4.0 software. Signal intensity (SI) data are expressed as photon counts per milligram of wet tissue weight (pc/mg).
Plasma Stability
Mouse plasma (75 mL) was incubated with 20 mL (12 nmol) of ET A -Cy5.5 solution at 37uC using an Eppendorf Thermomixer comfort (Eppendorf AG, Hamburg, Germany). At different time points (0 and 30 minutes and 1, 3, 5, and 24 hours; n 5 3), proteins were precipitated by addition of acetonitrile and centrifugation at 13,000 rpm (10 minutes, 16,000g) using an Eppendorf centrifuge (5415D, Eppendorf AG). Supernatants were filtered and subjected to RP-HPLC analysis (for conditions, see above), and the area under the corresponding peak was measured. Average values were determined in three independent experiments with probe duplicates. Values at time point 0 minutes were assigned to 100% tracer amount.
Statistics
All data are presented as means 6 standard error of the mean (SEM). Statistical differences between the predosed and the control group of animals were analyzed with an unpaired, two-tailed Student t-test using the InStatprogram (GraphPad Software, San Diego, CA). A p value of , .05 was considered to indicate a statistically significant difference.
Results
We investigated the biodistribution of the previously developed ET A R selective optical imaging probe ET A -Cy5.5 (2) in wild-type CD-1 mice to assess its capability for in vivo imaging studies. The results of the examinations are summarized in Table 1 and Table 2 Figure 2 shows the time courses of organ fluorescence intensities after administration of 2 nmol of the tracer. At 10 minutes after injection, the highest SIs are found in the lung (. 1.3?10 5 pc/mg), in the liver (. 7.5?10 4 pc/mg), and in the kidneys (. 7.4?10 4 pc/mg), whereas the brain shows the lowest SI (, 1.4?10 4 pc/mg). After 30 minutes, any organ except the spleen shows a higher fluorescence intensity compared with 10-minute values. The highest ratio of increase is found in muscle (. 1.3), heart (. 1.2), and liver (. 1.2). Values after 60 minutes reveal a high increase of fluorescence intensities in the lung and heart, whereas the liver and kidney show attenuation of the signal. The results at time points 3 and 5 hours show a noticeably high increase in fluorescence SI in the lung (. 2.8?10 5 pc/mg). Also, a slight increase in fluorescence SI is found in spine and muscle, but, overall, intensities are lower than for the heart, kidney, or liver. Comparing the kidneys and the liver, it is noticeable that values for the liver stay nearly constant at < 8.7?10 4 pc/mg, whereas the signal in the kidneys decreases from 7.3?10 4 pc/mg to , 5.5?10 4 pc/mg over this period of time. The heart shows a decrease in fluorescence intensity from 7.3?10 4 pc/mg at 1 hour to , 5.3?10 4 pc/mg at 3 and 5 hours. After 24 and 48 hours, SIs have attenuated to values # 5.0?10 4 pc/mg in all organs except for the lung, where the tracer seems to accumulate, and SI values are still . 2.4?10 5 pc/mg. Figure 3 shows the effect of predosing on mean fluorescence intensities of selected organs. The specificity of tracer uptake is best described when looking at the ratio of total to nonspecific binding in the heart (see Figure 3A) . In contrast to the values when the tracer was given alone (see above), the intensities after predosing drop from 5.2?10 4 pc/mg to , 3.5?10 4 pc/mg in the first 60 minutes postinjection and do not rise markably above this value until 48 hours after administration. The ratio of total to nonspecific binding rises from 1.5 (p , .01) at 30 minutes to 2.1 (p , .0001) after 60 minutes and at 3 and 5 hours is still high at 1.6 (p , .005) and 1.5 (p , .0001), respectively. The predosing effect in the lung (see Figure  3B ) is significant at time points from 1 to 5 hours, with ratios of total to nonspecific binding of 1.4 (p , .05), 1.4 (p , .005), and 2.0 (p , .001). After 24 and 48 hours, predosing had no influence on the fluorescence intensities anymore. In the liver, the effect of predosing is not as accentuated as in other organs (see Figure 3C ). At 30 minutes, the ratio of total to nonspecific binding is . 1.7 (p , .005), but at 60 minutes and 3 hours, it is reduced to 1.3 and 1.1, respectively. At 5 hours, the ratio rises to . 1.7 (p # .0005) again. When examining the values for the kidneys, it is most noticeable that at 10 minutes, the SIs are significantly higher (p # .001) after predosing, indicating a higher amount of free tracer owing to PD 156707occupied sites resulting in an enhanced excretion. Later on, the values attenuate constantly over time, showing no differences with respect to predosing (see Figure 3D ). Figure 4 shows selected results of the displacement experiments at time point 60 minutes in comparison with the results from the predosing studies. Whereas in the heart, predosing and displacement show significant effects on fluorescence signal reduction with ratios of total to nonspecific binding of 2.1 (p , .0001) and 1.5 (p , .01), the effect of predosing in the lung (ratio of total to nonspecific binding 5 1.4, p , .05) cannot be reproduced by displacement experiments. Here, the reduction in signal intensity is , 10%. A representative organ panel from biodistribution studies is displayed in Figure 5 Organs are placed on a petri dish. Figure 5 , C to E, shows white light and FR images (raw and color coded) of hearts 60 minutes after injection of the tracer (left to right: C, ET A -Cy5.5 alone; D, predosing experiment; E, displacement experiment). Fluorescence is highest in the ET A -Cy5.5 group and clearly decreases after predosing or displacement. Figure 6 shows the results of the in vitro stability assay with mouse plasma. The percentage of intact tracer in the supernatant after given time points is recorded. The values show an exponential decrease to approximately 20% after 24 hours of incubation. 
Discussion
Our biodistribution data reveal that it is feasible to image ET A Rs in vivo using the previously developed highly affine fluorescent tracer. Binding specificity was shown by both competition and displacement experiments with specific tracer uptake in target tissue such as heart and lung. This reflects the biology of receptor distribution in vivo with high abundance of ET A Rs in these organs. 25, 26 A phenomenon well known from other target-specific imaging approaches is that specific probe binding is overlaid by unspecific tracer distribution in the early ''perfusions phase.'' 27, 28 According to our data, imaging 1 to 5 hours after injection of the probe revealed the best results with respect to imaging ET A R expression. At later time points, the specificity of the data is spoiled by clearance of the probe via internalization, as well as by probe degradation, as shown by the plasma stability assay. . Stars indicate significant differences in intensities (*p # .01; **p # .005; ***p # .0001; note the difference in scale). Between 30 minutes and 5 hours, there is a highly specific signal in heart tissue, whereas in the lung, intensities rise constantly from 10 minutes to 5 hours in nonpredosed animals. After 1 day, the tracer has accumulated in lung tissue. The liver shows specific tracer uptake after 30 minutes and 5 hours. Attenuation of the signal to background values is observed after 24 and 48 hours. Signal intensity in the kidneys attenuate constantly over time. In particular, the highly significant signal yield after predosing at 10 minutes indicates a first fast washout via these organs. The excretion route of the tracer is found to be divergent between liver and kidney, with a first, fast washout via the kidneys and a later elimination by the liver (see Figure 2A and Figure 3 , C and D). The latter interestingly seems to appear in a period from 1 to 3 hours, where the specificity of tracer binding in liver tissue is diminished, emphasizing a high amount of metabolites present at this time point. This is in accordance with findings for radiolabeled ET A R ligands, and it has been explained by the assumption that metabolization in the liver is a rapid process. 29 In particular, the high value of fluorescence in the kidneys after predosing at time point 10 minutes indicates that the hydrophilic nature of the tracer promotes renal excretion. This is in contrast to experiments using radioabeled nonpeptidic compounds, which usually are much more lipophilic. A high degree of specific binding in the kidneys was not observed, reflecting the predominance of the ET B R subtype in these organs. 30, 31 Lung tissue plays an important role in ET receptor ligand elimination. 32 In normal and pathologic conditions, lung ET B Rs mediate the clearance of ET-1 from plasma by internalization of the ligand-receptor complex. Whereas ET A R is recycled to a significant extent after internalization, ET B R usually is degraded by lysosomal processing. 33, 34 In one case, the internalization of ET A Rs after incubation with an ET A R-selective antagonist has also been observed, 35 indicating that this processing pathway is also possible for the applied fluorescent tracer. In lung tissue, a large amount of ET A Rs and ET B Rs are present. The predominance of one subtype and concentration of receptors differ greatly with species and tissue type. For instance, airway smooth muscle cells from porcine origin express ranges from 7:3 to 3:7 for ET A to ET B ratios. [36] [37] [38] The tracer uptake in lung tissue is found to be significantly specific at medial time points from 1 to 5 hours, where a high predosing effect can be observed. Interestingly, displacement experiments 1 hour after injection of the tracer do not significantly reduce the fluorescence intensity in this tissue. This can be explained by an elevated degree of internalization, which was already discussed in an investigation with the radiolabeled tracer [ 18 F]-ET-1. 39 Here, the investigators found rapid clearance of the endogenous ligand by lung and kidney via ET B -mediated internalization, preventing visualization of target tissue such as the myocardium. In addition, a fast accumulation in the liver is described, relating to ET A R binding and metabolic activity.
Compared with traditional biodistribution studies, working with fluorescent probes and FRI is fundamentally different with respect to probe quantification. Given that (1); lesser to no intensity is found in the spleen (3), brain (7) , and muscle (2) . C-E, White light and NIRF images (raw and color coded, left to right; numbers indicate photon counts per pixel, 60-minute images) of explanted hearts after administration of 2 nmol of the tracer (C, ET A -Cy5.5 alone; D, predosing experiment; 2.0 mmol PD 156707 10 minutes prior to tracer administration; E, displacement experiment, 2.0 mmol PD 156707 50 minutes after tracer administration). FRI is only a semiquantitative imaging method, differences in the fluorescence intensities of the organs may in part be explained by varying absorption and scattering properties of the tissues examined. We intended to reduce the absorption by hemoglobin by tissue perfusion prior to organ harvesting. However, lung tissue itself is per se more transparent to light compared with liver or muscle, for example, which in part explains the different fluorescent signal gains for different organ subtypes. 40, 41 The assessment of tracer specificity (ie, ratios of total to nonspecific binding), however, should remain unchanged despite different scattering and absorption properties. More advanced fluorescence imaging techniques such as FMT [15] [16] [17] 42 or modified imaging systems, for example, systems using polarized fluorescent light, 43, 44 may correct at least in part for this systematic shortcoming. Thus, further studies are warranted to elucidate this point. Furthermore, direct in vivo to ex vivo correlations should be possible, for example, by fluorescence microscopy. In conclusion, we successfully developed a new fluorescent ET A R tracer that shows specific binding to murine ET A Rs in vivo. Further studies are currently in progress to investigate the ''diagnostic performance'' of this new molecular imaging probe in different pathologies, for example, tumor tissues, where ET A R density is regulated. Figure 6 . Plasma stability determination in vitro. Percentage of intact fluorescent probe (mean 6 SEM) left after incubation at given time points (0, 30, and 60 minutes; 3, 5, and 24 hours). The measured value at time point 0 minutes was assigned to 100% tracer amount.
